Dr. Mark Shelton is an accomplished clinical research scientist with 25 years of experience and comprehensive knowledge in design and clinical development, as evidenced by a portfolio of manuscripts and abstract presentations, predominantly related to clinical pharmacology.
After obtaining his PharmD degree, Dr. Shelton completed a Clinical Pharmacy Residency at Thomas Jefferson University Hospital, followed by an American College of Clinical Pharmacy-sponsored fellowship at the University at Buffalo (UB). Dr. Shelton started his professional career on the faculty at UB, leading a small Clinical Pharmacology Unit to conduct studies within an outpatient HIV clinic, progressing to a larger inpatient unit to focus on studies in healthy subjects. This tenure was followed by a stint as a Clinical Pharmacologist at GlaxoSmithKline for six years, where he worked on both antivirals and oncology assets. Subsequently, Dr. Shelton worked as a Clinical Scientist focusing on Hepatitis C at Gilead, and in Clinical Operations for early phase Oncology studies at INC Research and Quintiles, prior to his current position as Senior Clinical Pharmacologist at Certara.
Dr. Shelton has an extensive record of clinical pharmacology publications in peer-reviewed journals and presentations at various international scientific conferences. Dr. Shelton has lead and executed a variety of clinical pharmacology and early phase development programs, including close interface with regulatory agencies, sponsors, and investigators. Examples include development/implementation of clinical pharmacology plans for two HIV protease inhibitors, innovative strategy for a neuraminidase inhibitor for pandemic influenza, an early, all-oral regimen for the treatment of hepatitis C, and strategic design and implementation of a portfolio of oncology studies designed to explore alternative indications.